<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>volatility on FinanClub</title>
    <link>https://finan.club/tags/volatility/</link>
    <description>Recent content in volatility on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Wed, 17 Jan 2024 09:04:41 +0000</lastBuildDate><atom:link href="https://finan.club/tags/volatility/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>MRNA</title>
      <link>https://finan.club/us/mrna/</link>
      <pubDate>Wed, 17 Jan 2024 09:04:41 +0000</pubDate>
      
      <guid>https://finan.club/us/mrna/</guid>
      <description>score:-55
Chances: Moderna&amp;rsquo;s product pipeline includes a wide range of modalities, such as prophylactic vaccines, cancer vaccines, and localized regenerative therapeutics, providing opportunities for significant future growth. The company&amp;rsquo;s focus on intratumoral immuno-oncology and systemic intracellular therapeutics reflects a strong commitment to addressing complex medical challenges with innovative solutions.</description>
    </item>
    
    <item>
      <title>IMGN</title>
      <link>https://finan.club/us/imgn/</link>
      <pubDate>Tue, 16 Jan 2024 09:03:26 +0000</pubDate>
      
      <guid>https://finan.club/us/imgn/</guid>
      <description>score:155
Chances: ImmunoGen has seen solid earnings estimate revision activity over the past two months. The company belongs to a strong industry with growing optimism about its earnings prospects. ImmunoGen made it to the Zacks Rank #1 (Strong Buy) momentum stocks list. ImmunoGen has announced inducement grants under Nasdaq Listing Rule.</description>
    </item>
    
  </channel>
</rss>
